CD24 and prostate cancer: CD44+/CD24–/low cells have been described as breast [96] and prostate cancer [97] stem cells; stem-like properties, including increased proliferation [96], angiogenesis [98], and resistance to chemotherapy [99], have been attributed to CD44+/CD24–/low NSCLC [100], and ovarian cancer cells as well [101].